Prognosis of BK Polyomavirus Nephropathy: 10-Year Insights From 133 Kidney Transplant Recipients
If you or a loved one has had a kidney transplant, you’ve probably heard about the risks of infection—one of the most common and dangerous is from the BK polyomavirus (BKV). For up to 10% of transplant recipients, this virus progresses to BK virus-associated nephropathy (BKVN), a tubulointerstitial kidney inflammation that can damage the new organ and even lead to graft loss. But what happens to patients with BKVN long-term? A 10-year study from China’s Sun Yat-Sen University offers critical answers.
The Study: Tracking BKVN Outcomes Over a Decade
Researchers from the First Affiliated Hospital of Sun Yat-Sen University (Guangzhou) analyzed data from 133 kidney transplant recipients diagnosed with biopsy-proven BKVN between 2007 and 2017. They followed patients for an average of 14.4 months (and up to 9 years) to measure:
- Graft survival (whether the new kidney kept working)
- Changes in kidney function (via estimated glomerular filtration rate, or eGFR—a key marker of kidney health)
- Viral clearance (when BKV disappeared from urine [viruria] or blood [viremia])
- The impact of secondary rejection (when the immune system attacks the graft after reducing immunosuppression to fight BKVN)
This is one of the longest follow-up studies of BKVN to date, making its findings particularly valuable for patients and clinicians.
What Is BKVN? A Quick Refresher
BKV is a common virus—up to 80% of people are infected by age 10—but it usually stays dormant. For kidney transplant recipients, powerful immunosuppression drugs (to prevent graft rejection) can reactivate the virus. It typically spreads in two stages:
- Viruria: BKV is found in urine (most common, often harmless).
- Viremia: BKV enters the bloodstream (a red flag for kidney damage).
If left unmanaged, viremia can lead to BKVN—a serious condition where the virus infects kidney tubules, causing inflammation, scarring, and loss of function.
Key Findings: How BKVN Affects Transplant Survival
The study’s most striking results center on graft survival—how long the new kidney kept working:
- 1-year survival: 99.2% (nearly all kidneys worked after 1 year)
- 3-year survival: 90.7% (1 in 10 kidneys failed by year 3)
- 5-year survival: 85.7% (1 in 7 kidneys failed by year 5)
Overall, 13.5% of patients lost their grafts (either because the kidney stopped working or the patient died with a functional graft).
Pathologic Stage Matters Most
BKVN is graded by pathologic stage (A, B, C) based on how much the virus has damaged the kidney. The study confirmed what clinicians suspected: higher stage = worse outcomes. Stage C patients (most severe damage) had a 23.1% graft loss rate—more than 10x higher than stage A patients (0% loss).
Two Big Risks for Poor Outcomes: Rejection and Persistent Infection
The study identified two key factors that worsened prognosis:
1. Secondary Rejection
To treat BKVN, doctors reduce immunosuppression—this helps the immune system fight the virus but raises the risk of rejection. In this cohort:
- 6% of patients developed acute rejection after reducing meds.
- Patients with rejection had significantly lower eGFR (21.6 vs. 33.5 mL/min/1.73m²) than those without—meaning their kidneys worked much worse.
Importantly, the rejection rate here (6%) was lower than the 8–50% reported in other studies. Researchers credit this to cautious immunosuppression reduction and strict biopsy criteria (rejection was only confirmed if blood vessels were inflamed, not just tubules).
2. Persistent BKV Infection
Even after treatment, 40 of 65 patients who got a repeat biopsy still had positive SV40-T antigen—a marker of active BKV in kidney tissue. These patients had:
- Worse kidney function (eGFR: 26.5 vs. 42.6 mL/min/1.73m²)
- Higher viral loads in urine (1.4 million vs. 130,000 copies/mL)
Persistent infection didn’t affect graft survival yet, but the team warns it’s a red flag for long-term damage.
Good News: Most Viremia Clears—But Viruria Lingers
One bright spot: 90% of patients cleared BKV from their blood (viremia) within 24.8 months. Viruria (virus in urine) was harder to eliminate—only 19.5% of patients saw it disappear. But here’s the surprise: persistent viruria didn’t affect outcomes. Patients with ongoing viruria had similar kidney function and graft survival to those without.
This suggests that viremia (bloodborne virus) is a bigger threat than viruria—something clinicians can use to prioritize treatment.
What This Means for Patients and Clinicians
The study’s biggest takeaway is simple: early detection and cautious management save kidneys.
- Routine BKV screening: Most patients in this study were diagnosed after their kidney function worsened. If centers screened for BKV regularly (via urine/blood tests), they could catch infections earlier—before permanent damage.
- Balance immunosuppression: Reducing meds is necessary to fight BKVN, but it must be done slowly. This study’s low rejection rate shows that “modest” reductions work best.
- Monitor for rejection: Patients with BKVN need regular kidney function checks and biopsies to catch rejection early.
Limitations to Keep in Mind
No study is perfect. This one had a few key limitations:
- Retrospective design: Researchers looked back at existing data, which can introduce bias.
- Biopsy bias: Biopsies were done only when patients had symptoms (like high creatinine), so mild cases might have been missed.
- Treatment heterogeneity: Patients came from different centers, so treatment plans varied.
Conclusion: BKVN Is Manageable—But Vigilance Is Key
For kidney transplant recipients, BKVN is a serious risk—but it’s not a death sentence for the graft. This 10-year study shows that:
- Most patients keep their kidneys working for years if treated early.
- Higher pathologic stage, secondary rejection, and persistent infection are red flags for poor outcomes.
- Routine screening and cautious immunosuppression are the best tools to fight BKVN.
Prognosis of BK Polyomavirus Nephropathy: 10-Year Analysis of 133 Renal Transplant Recipients at a Single Center
Xu-Tao Chen, Shi-Cong Yang, Jun Li, Rong-Hai Deng, Wen-Fang Chen, Jiang Qiu, Li-Zhong Chen, Chang-Xi Wang, Gang Huang
Department of Organ Transplantation and Department of Pathology, The First Affiliated Hospital of Sun Yat-Sen University, Guangzhou, China
Published in Chinese Medical Journal (2019)
doi.org/10.1097/CM9.0000000000000085
Was this helpful?
0 / 0